FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
With the recent regulatory approvals of novel immunotherapies (e.g. PD-1 and PD-L1 antibodies) for metastatic or inoperable urothelial carcinoma, it seems logical that these and other similar agents be tested in earlier settings. There are many ongoing adjuvant clinical trials (discussed in a previous article);7 however, the neoadjuvant setting is being less robustly explored. Actually, the neoadjuvant setting is quite an ideal setting for biologic exploration, since there is generally readily available tissue for translational correlative studies. Since there are no accepted standard of care neoadjuvant regimens for patients “unfit” for cisplatin with high-risk muscle-invasive urothelial carcinoma, it stands to reason that we emphasize accrual to clinical trials focused on evaluation of these patients. Below, we highlight a few trials specifically for patients “unfit” for cisplatin; a couple trials using combination checkpoint inhibitors and also a trial combining a checkpoint inhibitor with cytotoxic chemotherapy. Should any of these trials render promising results, our field should prioritize continued trial development for this fairly large “unfit” for cisplatin patient population. As this patient population represents a significant unmet medical need, our field needs to continue to evaluate novel systemic therapy regimens with potential to offer improvement of long-term outcomes.
Written by: Evan Yu, MD
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy
Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
1. Grossman HB et al. N Engl J Med 2003; 349:859-66.
2. International Collaboration of Trialists et al. J Clin Oncol 2011; 29:2171-7.
3. Zaid HB et al. Urology 2014; 83:75-80.
4. Lee FC et al. Adv Urol 2013; 2013:317190.
5. Galsky MD et al. J Clin Oncol 2011; 29:2432-8.
6. Sternberg CN et al. Eur Urol 2013; 63:58-66.
7. Yu, EY. (2017, May 18). No…the ball game is not over...adjuvant trials of PD-1 and PD-L1 antibodies in urothelial carcinoma must go on!